Trial Profile

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Ramucirumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Large cell carcinoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

18 Jan 2021 Status changed from active, no longer recruiting to completed.
18 Dec 2020 Planned End Date changed from 30 Mar 2021 to 15 Jan 2021.
19 Aug 2020 Results published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com